ArticleACG case reports journal2025
Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations.Diagnostics (Basel, Switzerland) · 2026Article
- Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity.International journal of molecular sciences · 2025Review
- Tirzepatide-Induced Liver Injury: A Rare Complication.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced liver injury (DILI) secondary to tirzepatide use. We report the experience of a 76-year-old woman who developed acute hepatitis following 8 weeks of tirzepatide use and a sixteen-pound weight loss. She was found to have elevated liver enzymes, and liver biopsy confirmed DILI. Though the mechanism underlying this DILI remains unknown, physicians should be aware of this rare side effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.